Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).
Benjamin J. Solomon
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Scott N. Gettinger
Research Funding - Pfizer
Gregory J. Riely
Consultant or Advisory Role - Abbott Laboratories; ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Novartis; Pfizer
Shirish M. Gadgeel
Honoraria - Pfizer
Research Funding - Pfizer
Hiroshi Nokihara
No relevant relationships to disclose
Ji-Youn Han
No relevant relationships to disclose
Toyoaki Hida
Research Funding - Chugai Pharma; Novartis; Pfizer
Miyako Satouchi
Honoraria - Pfizer
Research Funding - Pfizer
Editta Baldini
No relevant relationships to disclose
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi
Nobuyuki Yamamoto
Honoraria - Pfizer
Leora Horn
Consultant or Advisory Role - Astellas Pharma (U); Boehringer Ingelheim (U); Genentech (U); OSI Pharmaceuticals (U)
Research Funding - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Genentech; Xcovery
Vanessa Roberts Tassell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Anna Polli
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
D. Ross Camidge
Consultant or Advisory Role - Pfizer